| 刘 屹,丰 航,许凡凡,张鑫雨,何 恒,张 鹏,朱亚宁.三阴性乳腺癌术后辅助化疗方案的药学研究[J].现代生物医学进展英文版,2019,19(5):880-885. |
| 三阴性乳腺癌术后辅助化疗方案的药学研究 |
| Pharmaceutical Research on Postoperative Adjuvant Chemotherapy for Three Patients with Three Negative Breast Cancer |
| Received:July 16, 2018 Revised:August 12, 2018 |
| DOI：10.13241/j.cnki.pmb.2019.05.019 |
| 中文关键词: 三阴性乳腺癌 术后辅助化疗 化疗方案 药学服务 |
| 英文关键词: Triple negative breast cancer(TNBC) Postoperative adjuvant chemotherapy Chemotherapy regimens Pharmaceutical service |
| 基金项目:国家自然科学基金项目（NSFC 81402012）；陕西省自然科学基金项目（2015JQ8321） |
| Author Name | Affiliation | E-mail | | LIU Yi | Department of oncology, Shaanxi People's Hospital, Xi'an, Shaanxi, 710068, China | liuyi926999@yeah.net | | FENG Hang | Department of pharmacology, Xi'an, Shaanxi, 710068, China | | | XU Fan-fan | Department of pharmacology, Xi'an, Shaanxi, 710068, China | | | ZHANG Xin-yu | Fourth Cadet Brigade, Air Force Medical University, Xi'an, Shaanxi, 710032, China | | | HE Heng | Department of pharmacology, Xi'an, Shaanxi, 710068, China | | | ZHANG Peng | Department of pharmacology, Xi'an, Shaanxi, 710068, China | | | ZHU Ya-ning | Department of pharmacology, Xi'an, Shaanxi, 710068, China | |
|
| Hits: 991 |
| Download times: 853 |
| 中文摘要: |
| 摘要 目的：调查三阴性乳腺癌术后辅助化疗三种方案的临床应用情况，制订药学监护点。方法：收集我院2009年12月至2017年5月168例三阴性乳腺癌患者，化疗方案选用TAC、TP或AC→T方案，对三组患者进行具体分析。结果：胃肠道反应：TAC组Ⅰ度8例，Ⅱ度28例；AC→T组Ⅰ度4例，Ⅱ度100例；Ⅲ度4例；TP组Ⅱ度20例，Ⅲ度4例。骨髓抑制：TAC组Ⅱ度32例，Ⅲ度4例；AC→T组Ⅱ度92例，Ⅲ度16例；TP组Ⅱ度20例，Ⅲ度4例。三组不同化疗方案TNBC患者的胃肠道反应、骨髓抑制的发生情况比较差异均无统计学意义(P>0.05)。一年肿瘤无进展生存率：TAC 88.9%；AC→T 92.6%；TP 100%，平均化疗费用：TAC 20686.94±199.87元；AC→T 19470.83±150.988元；TP 12895.42±276.341元，平均住院天数为8.808±0.2792天；10.213±0.2429天；10.958±0.3782天。结论：在TAC、TP和AC→T方案中，TP方案治疗三阴性乳腺癌的临床疗效可，副反应少，费用少，是较优选的治疗方案。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical application of three kinds of postoperative adjuvant chemotherapy (TAC, TP, AC→T) for the three negative breast cancer, and make pharmaceutical care point. Methods: 168 cases of three negative breast cancer pa- tients admitted in our hospital and given TAC TP, or AC→T chemotherapy regimens from December 2009 to May 2017 ,were collected and analyzed. Results: Gastrointestinal reaction Ⅰ and Ⅱ were found in 8 and 28 cases of TAC group, gastrointestinal reaction Ⅰ, Ⅱ and Ⅲ were found in 4, 100 and 4 cases of AC→T group, gastrointestinal reaction Ⅱ and Ⅲ were found in 20 and 4 cases in the TP group. Bone marrow suppression Ⅱ and Ⅲ were found in 32 and 4 cases of TAC group, 92 and 6 cases of AC→T group, 20 and 4 cases in the TP group. No significant difference was found in the incidence of gastrointestinal reaction and bone marrow suppression between TNBC patients undergoing different chemotherapy regimens(P>0.05). The tumor progression-free survival rate was 88.9% in TAC group, 92.6% in the AC→T group, 100% in the TP group. The average chemotherapy costs were 20686.94±199.87, 19470.83±150.988 and 12895.42±276.341 yuan in the TAC, AC→T and TP group, the average hospitalization days were 8.808±0.2792, 10.213±0.2429, 10.958±0.3782 days in the TAC, AC→T and TP group. Conclusion: Among TAC, TP and AC→T chemotherapy regimens, TP chemotherapy regimen was most effective in the treatment of TNBC with less adverse reactions and lower treatment costs. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
